Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease

Eligibility: for people ages 10-65 (full criteria)
Location: at Los Angeles, California and other locations
Dates: study started March 2022
completion around June 2026
Principal Investigator: by Anjay Rastogi, MD, PhD

Anjay Rastogi

Description

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Official Title

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

Keywords

Proteinuric Kidney Disease, Kidney Diseases, VX-147

Eligibility

You can join if…

Open to people ages 10-65

APOL1 genotype of G1/G1, G2/G2, or G1/G2
Proteinuric kidney disease

You CAN'T join if...

Solid organ or bone marrow transplant
Uncontrolled hypertension
History of diabetes mellitus
Known underlying cause of kidney disease including but not limited to sickle cell disease

Other protocol defined Inclusion/Exclusion criteria apply.

Locations

UCLA Division of Nephrology completed
Los Angeles California 90095 United States
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center accepting new patients
Torrance California 90502 United States
Cedars-Sinai Medical Center accepting new patients
Los Angeles California 90048 United States
Kaiser Permanente - Los Angeles Medical Center accepting new patients
Los Angeles California 90027 United States
Amicis Research Center accepting new patients
Granada Hills California 91344 United States
Renal Consultants Medical Group accepting new patients
Granada Hills California 91344 United States
Eastside Clinical Research Associates accepting new patients
Los Angeles California 90022 United States

Lead Scientist at UCLA

Anjay Rastogi, MD, PhD
Professor of Clinical, Medicine. Authored (or co-authored) 90 research publications

Details

Status: accepting new patients
Start Date: March 2022
Completion Date: June 2026 (estimated)
Sponsor: Vertex Pharmaceuticals Incorporated
Links: Sign up for this study
ID: NCT05312879
Phase: Phase 2/3 Kidney Disease Research Study
Study Type: Interventional
Participants: Expecting 466 study participants
Last Updated: April 16, 2025

I’m interested in this study!